Brief: Sorrento Announces Significant Positive Pivotal Trial Results As Assessed By An Independent Review Committee With Matured Long-Term Follow-Up Data Of Abivertinib For Treatment Of Advanced Non-Small Cell Lung Cancer

Sorrento Therapeutics

23/08/2022 14:49

Aug 23 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO ANNOUNCES SIGNIFICANT POSITIVE PIVOTAL TRIAL
RESULTS AS
ASSESSED BY AN INDEPENDENT REVIEW COMMITTEE (IRC) WITH MATURED
LONG-TERM (OVER THREE YEARS) FOLLOW-UP DATA OF ABIVERTINIB FOR
THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    * SORRENTO THERAPEUTICS INC - OVERALL RESPONSE RATE (ORR) AS
CONFIRMED BY IRC WAS 56.5%

Source text for Eikon:  ID:nGNXmgnmm 
Further company coverage:  SRNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))